Shaft orbit pattern recognition for fault diagnosis of Induction motor using Neural Network

P. Konar,P. Chattopadhyay

Abstract:

What problem does this paper attempt to address?

Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model

Yang Liu,Xiaoruo Zhu,Shiliang Ji,Zhen Huang,Yuhui Zang,Ying Ding,Junfeng Zhang,Zhi Ding

DOI: https://doi.org/10.1080/10717544.2022.2122632

IF: 6.819

2022-09-15

Drug Delivery

Abstract:Colchicine (Col) is used to prevent and treat acute gout flare; however, its therapeutic use is strictly limited owing to severe gastrointestinal side effects after oral administration. Therefore, we developed a dissolvable Col-loaded microneedle (MN) with hyaluronic acid to deliver Col via the transdermal route. We studied the preparation, mechanical properties, skin insertion, skin irritation, drug content, and transdermal release of the Col-loaded MN. The pharmacokinetics of Col after Col-loaded MN application were compared with those of Col solution gavage over 24 h. Knee joint edema evaluation and the hindfoot mechanical threshold test were conducted to determine the pharmacodynamic profile. The dissolvable Col-loaded MN possessed sufficient mechanical strength to penetrate the skin and release the loaded drug. No skin irritation was observed for 3 days after application. We found that 3.36-fold more Col contained in MNs was delivered through the skin compared with that in gel in vitro , and moderate relative bioavailability in vivo . The Col-loaded MN significantly relieved swollen knee joints and mechanical hypernociception in an acute gout model in rats. The dissolvable Col-loaded MN array reduced inflammation and pain via topical administration when acute gout occurred. Reducing the gastrointestinal side effects of Col-loaded MNs is expected to optimize the therapeutic effects of Col and improve patient compliance.

pharmacology & pharmacy
Rapidly separating dissolving microneedles with sustained-release colchicine and stabilized uricase for simplified long-term gout management

Yao Yang,Zimu Li,Ping Huang,Jiachan Lin,Jinyuan Li,Kexin Shi,Jiahui Lin,Jingwen Hu,Zhuoxian Zhao,Yongkang Yu,Hongzhong Chen,Xiaowei Zeng,Lin Mei

DOI: https://doi.org/10.1016/j.apsb.2023.02.011

Abstract:Despite growing prevalence and incidence, the management of gout remains suboptimal. The intermittent nature of the gout makes the long-term urate-lowering therapy (ULT) particularly important for gout management. However, patients are reluctant to take medication day after day to manage incurable occasional gout flares, and suffer from possible long-term toxicity. Therefore, a safe and easy-to-operate drug delivery system with simple preparation for the long-term management of gout is very necessary. Here, a chitosan-containing sustained-release microneedle system co-loaded with colchicine and uricase liposomes were fabricated to achieve this goal. This microneedle system was confirmed to successfully deliver the drug to the skin and maintain a one-week drug retention. Furthermore, its powerful therapeutic potency to manage gout was investigated in both acute gouty and chronic gouty models. Besides, the drug co-delivery system could help avoid long-term daily oral colchicine, a drug with a narrow therapeutic index. This system also avoids mass injection of uricase by improving its stability, enhancing the clinical application value of uricase. In general, this two-drug system reduces the dosage of uricase and colchicine and improves the patient's compliance, which has a strong clinical translation.
Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects

Hong Yi,Haojie Yu,Li Wang,Yu Wang,Chenguang Ouyang,Basem E Keshta

DOI: https://doi.org/10.1016/j.actbio.2024.08.032

2024-10-01

Abstract:Gouty arthritis (GA) is caused by monosodium urate (MSU) crystals deposition. GA is difficult to cure because of its complex disease mechanism and the tendency to reoccur. GA patients require long-term uric acid-lowering and anti-inflammatory treatments. In the past ten years, as a painless, convenient and well-tolerated new drug transdermal delivery method, microneedles (MNs) administration has been continuously developed, which can realize various drug release modes to deal with various complex diseases. Compared with the traditional administration methods (oral and injection), MNs are more conducive to the long-term independent treatment of GA patients because of their safe, efficient and controllable drug delivery ability. In this review, the pathological mechanism of GA and common therapeutic drugs for GA are summarized. After that, MNs drug delivery mechanisms were summarized: dissolution release mechanism, swelling release mechanism and channel-assisted release mechanism. According to drug delivery patterns of MNs, the mechanisms and applications of rapid-release MNs, long-acting MNs, intelligent-release MNs and multiple-release MNs were reviewed. Additionally, existing problems and future trends of MNs in the treatment of GA were also discussed. STATEMENT OF SIGNIFICANCE: Gout is an arthritis caused by metabolic disease "hyperuricemia". Epidemiological studies show that the number of gouty patients is increasing rapidly worldwide. Due to the complex disease mechanism and recurrent nature of gout, gouty patients require long-term therapy. However, traditional drug delivery modes (oral and injectable) have poor adherence, low drug utilization, and lack of local localized targeting. They may lead to adverse effects such as rashes and gastrointestinal reactions. As a painless, convenient and well-tolerated new drug transdermal delivery method, microneedles have been continuously developed, which can realize various drug release modes to deal with gouty arthritis. In this review, the material structure, design strategy and future outlook of microneedles for treating gouty arthritis will be reviewed.
Trial of ABO and Rh blood typing with an automated blood cell counter.

N. Tatsumi,I. Tsuda,K. Inoue

DOI: https://doi.org/10.1111/J.1365-2257.1989.TB00194.X

1989-06-01

Abstract:We designed a method for ABO and Rh typing using a blood cell counter. Blood specimens were diluted with physiological saline, mixed with an antiserum, and incubated. The cell count and size distribution curves were obtained by an automated blood cell counter. The samples with agglutination had a decreased cell count and a characteristic size distribution curve with a population of doublet cells on the right side. The results were correlated with the degree of agglutination observed by the manual method, used as a reference. It should be possible to adapt blood cell counters for use in blood typing.
Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons

Shiji Liao,Guirong Qiu,Yanping Hu,Bohong Guo,Yuqin Qiu

DOI: https://doi.org/10.1208/s12249-023-02716-3

IF: 3.3

2023-12-19

AAPS PharmSciTech

Abstract:Colchicine is the first-line option for both the treatment and prophylaxis of gout flares. However, due to potentially severe side effects, the clinical use of colchicine is limited. A well-tolerated and safe delivery system for colchicine is widely desired. For this purpose, colchicine-loaded inseparable microneedles were fabricated using silk fibroin. Additionally, separable microneedles made of silk fibroin as the needle tips and PVP K30 as the base material were developed. Both types of microneedles were evaluated for their mechanical strength, swelling and dissolution characteristics, insertion abilities, degradation properties, in vitro penetration, skin irritation, and in vivo anti-gout effects. The results demonstrated that separable microneedles had greater mechanical strength and insertion ability. Moreover, the separable microneedles separated quickly and caused little skin irritation. In the pharmacodynamic test, mice with acute gouty arthritis responded significantly to treatment with separable microneedles. In conclusion, the separable silk fibroin-based microneedles provide a promising route for colchicine delivery.
Preparation of combined colchicine with loxoprofen sodium loaded in dissolvable microneedles and its anti-gouty arthritis effect

Mingxue Liu,Huimin Yang,Yu Wang,Wanting Fu,Changle Dong,Aoqi Ye,Yifeng Zou,Shuping Sun,Di Han,Hongling Zhang,Yinsheng Qiu,Lingyun Xu

DOI: https://doi.org/10.1016/j.jddst.2024.106471

IF: 5

2024-12-05

Journal of Drug Delivery Science and Technology

Abstract:Both colchicine (Col) and loxoprofen sodium (LS) are first-line drugs for gouty arthritis (GA). Dissolvable microneedles (DMNs) represent an innovative transdermal drug delivery system (TDDS) that maximizes the therapeutic effect of drugs. In this paper, a novel TDDS of combined Col with LS loaded in DMNs (Col-LS-DMNS) was prepared to treat GA. To assess the synergistic effects of Col and LS, cell viability assays were conducted using monosodium urate (MSU)-induced HaCaT cells. The optimization of the Col-LS-DMNs formulation was carried out through sealing membrane puncture tests, single-factor experiments, and Box-Behnken response surface methodology. The quality of Col-LS-DMNs was assessed using high-performance liquid chromatography (HPLC), scanning electron microscopy (SEM), sealing membrane puncture tests, in vitro mouse skin puncture experiments, and Franz diffusion cell assays. The therapeutic effect of Col-LS DMNs on GA through animal experiments. Results demonstrated that Col and LS exhibit a synergistic effect, with optimal mass ratio of 1:1. The optimal formulation included PVP K30 and CMC Na at a mass ratio of 10:1, with 63% water content and a mixed dosage of Col and LS of 42 mg. The drug content in Col-LS-DMNs was (19.11±0.65) μg of Col and (20.69±0.89) μg of LS per tablet. SEM imaging revealed that the needle tips were conical. Additionally, Col-LS-DMNs exhibited favorable mechanical properties and caused minimal skin damage. After 24 hours, the cumulative permeation amount was (21.55±19.49) μg/cm 2 . Col-LS-DMNs significantly reduced MSU-induced ankle swelling and decreased serum concentrations of TNF-α, IL-6, and IL-1β in rats. In conclusion, Col-LS-DMNs represent a promising new treatment modality for GA. Graphical abstract Download: Download high-res image (334KB) Download: Download full-size image

pharmacology & pharmacy
Core–shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Rui Wang,Yanfang Sun,Han Wang,Tianqi Liu,Amin Shavandi,Lei Nie,Khaydar E. Yunusov,Guohua Jiang

DOI: https://doi.org/10.1039/d3tb02607h

IF: 7.571

2024-01-04

Journal of Materials Chemistry B

Abstract:An appropriate non-oral platform via transdermal delivery of drugs is highly recommended for the treatment of hyperuricemia. Herein, a core–shell structured microneedle patch with programmed drug release functions was designed to regulate serum uric acid (SUA) levels for prolonged hyperuricemia management. The patch was fabricated using a three-step casting method. Allopurinol (AP), an anti-hyperuricemic drug, was encapsulated within the carboxymethyl cellulose (CMC) layer, forming the "shell" of the MNs. The MN's inner core was composed of polyvinylpyrrolidone (PVP) loaded with urate oxidase-calcium peroxide nanoparticles (UOx-CaO 2 NPs). When the as-fabricated core–shell structured microneedles were inserted into the skin, the loaded AP was first released immediately to effectively inhibit the production of SUA due to the water solubility of CMC. Subsequently, the internal SUA was further metabolized by UOx, leading to exposure of CaO 2 NPs. The sustained release of UOx accompanied by the decomposition of CaO 2 NPs contributed to maintaining a state of normal uric acid levels over an extended period. More attractively, uric acid could be oxidized due to the strong oxidant of CaO 2 , which was beneficial to the continuous consumption of uric acid. In vivo results showed that the as-fabricated MNs exhibited an excellent anti-hyperuricemia effect to reduce SUA levels to the normal state within 3 h and maintain the normouricemia state for 12 h. In addition, the levels of creatinine (Cr) and blood urea nitrogen (BUN) in the serum remained within the normal range, and the activities of adenosine deaminase (ADA) and xanthine oxidase (XOD) in the liver were effectively inhabited, mitigating the risk of liver and kidney damage for clinical anti-hyperuricemia management.

materials science, biomaterials
Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis

Rui Wang,Tongyao Liu,Xinhong Li,Enhao Lu,Yiting Chen,Kuankuan Luo,Tao Wang,Xueli Huang,Zhiwen Zhang,Shilin Du,Xianyi Sha

DOI: https://doi.org/10.1016/j.ajps.2024.100913

IF: 9.273

2024-01-01

Asian Journal of Pharmaceutical Sciences

Abstract:Flare and multiple recurrences pose significant challenges in gouty arthritis. Traditional treatments provide temporary relief from inflammation but fail to promptly alleviate patient pain or effectively prevent subsequent recurrences. It should also be noted that both anti-inflammation and metabolism of uric acid are necessary for gouty arthritis, calling for therapeutic systems to achieve these two goals simultaneously. In this study, we propose a biomimetic integrated nanozyme, HMPB-Pt@MM, comprising platinum nanozyme and hollow Prussian blue. It demonstrates anti-inflammatory properties by eliminating reactive oxygen species and reducing infiltration of inflammatory macrophages. Additionally, it rapidly targets inflamed ankles through the camouflage of macrophage membranes. Furthermore, HMPB-Pt@MM exhibits urate oxidase-like capabilities, continuously metabolizing locally elevated uric acid concentrations, ultimately inhibiting multiple recurrences of gouty arthritis. In summary, HMPB-Pt@MM integrates ROS clearance with uric acid metabolism, offering a promising platform for the treatment of gouty arthritis.
Glycyrrhizic acid modified Poria cocos polyscaccharide carbon dots dissolving microneedles for methotrexate delivery to treat rheumatoid arthritis

Qi Chen,Chengyuan Wu,Siwei Wang,Qiang Wang,Peiyun Wu,Lei Wang,Peiyu Yan,Ying Xie

DOI: https://doi.org/10.3389/fchem.2023.1181159

IF: 5.5

2023-05-24

Frontiers in Chemistry

Abstract:Introduction: Rheumatoid arthritis is an autoimmune disease characterized by chronic joint inflammation. Methotrexate is one of the most effective drugs for rheumatoid arthritis, but the adverse reactions caused by oral methotrexate greatly limit its clinical application. Transdermal drug delivery system is an ideal alternative to oral methotrexate by absorbing drugs into the human body through the skin. However, methotrexate in the existing methotrexate microneedles is mostly used alone, and there are few reports of combined use with other anti-inflammatory drugs. Methods: In this study, glycyrrhizic acid was first modified onto carbon dots, and then methotrexate was loaded to construct a nano-drug delivery system with fluorescence and dual anti-inflammatory effects. Then hyaluronic acid was combined with nano-drug delivery system to prepare biodegradable soluble microneedles for transdermal drug delivery of rheumatoid arthritis. The prepared nano-drug delivery system was characterized by transmission electron microscopy, fluorescence spectroscopy, laser nanoparticle size analyzer, ultraviolet-visible absorption spectroscopy, Fourier transform infrared spectroscopy, differential scanning calorimeter and nuclear magnetic resonance spectrometer. The results showed that glycyrrhizic acid and methotrexate were successfully loaded on carbon dots, and the drug loading of methotrexate was 49.09%. The inflammatory cell model was constructed by lipopolysaccharide-induced RAW264.7 cells. In vitro cell experiments were used to explore the inhibitory effect of the constructed nano-drug delivery system on the secretion of inflammatory factors by macrophages and the cell imaging ability. The drug loading, skin penetration ability, in vitro transdermal delivery and in vivo dissolution characteristics of the prepared microneedles were investigated. The rat model of rheumatoid arthritis was induced by Freund's complete adjuvant. Results: The results of in vivo animal experiments showed that the soluble microneedles of the nano drug delivery system designed and prepared in this study could significantly inhibit the secretion of pro-inflammatory cytokines and had a significant therapeutic effect on arthritis. Discussion: The prepared glycyrrhizic acid-carbon dots-methotrexate soluble microneedle provides a feasible solution for the treatment of Rheumatoid arthritis.

chemistry, multidisciplinary
Multimodal smart systems reprogramme macrophages and remove urate to treat gouty arthritis

Jingxin Xu,Mingjun Wu,Jie Yang,Dezhang Zhao,Dan He,Yingju Liu,Xiong Yan,Yuying Liu,Daojun Pu,Qunyou Tan,Ling Zhang,Jingqing Zhang

DOI: https://doi.org/10.1038/s41565-024-01715-0

IF: 38.3

2024-07-18

Nature Nanotechnology

Abstract:Gouty arthritis is a chronic and progressive disease characterized by high urate levels in the joints and by an inflammatory immune microenvironment. Clinical data indicate that urate reduction therapy or anti-inflammatory therapy alone often fails to deliver satisfactory outcomes. Here we have developed a smart biomimetic nanosystem featuring a 'shell' composed of a fusion membrane derived from M2 macrophages and exosomes, which encapsulates liposomes loaded with a combination of uricase, platinum-in-hyaluronan/polydopamine nanozyme and resveratrol. The nanosystem targets inflamed joints and promotes the accumulation of anti-inflammatory macrophages locally, while the uricase and the nanozyme reduce the levels of urate within the joints. Additionally, site-directed near-infrared irradiation provides localized mild thermotherapy through the action of platinum and polydopamine, initiating heat-induced tissue repair. Combined use of these components synergistically enhances overall outcomes, resulting in faster recovery of the damaged joint tissue.

materials science, multidisciplinary,nanoscience & nanotechnology
Promising Strategies for Transdermal Delivery of Arthritis Drugs: Microneedle Systems

Jitong Wang,Jia Zeng,Zhidan Liu,Qin Zhou,Xin Wang,Fan Zhao,Yu Zhang,Jiamiao Wang,Minchen Liu,Ruofei Du

DOI: https://doi.org/10.3390/pharmaceutics14081736

IF: 6.525

2022-08-20

Pharmaceutics

Abstract:Arthritis is a general term for various types of inflammatory joint diseases. The most common clinical conditions are mainly represented by rheumatoid arthritis and osteoarthritis, which affect more than 4% of people worldwide and seriously limit their mobility. Arthritis medication generally requires long-term application, while conventional administrations by oral delivery or injections may cause gastrointestinal side effects and are inconvenient for patients during long-term application. Emerging microneedle (MN) technology in recent years has created new avenues of transdermal delivery for arthritis drugs due to its advantages of painless skin perforation and efficient local delivery. This review summarizes various types of arthritis and current therapeutic agents. The current development of MNs in the delivery of arthritis drugs is highlighted, demonstrating their capabilities in achieving different drug release profiles through different self-enhancement methods or the incorporation of nanocarriers. Furthermore, the challenges of translating MNs from laboratory studies to the clinical practice and the marketplace are discussed. This promising technology provides a new approach to the current drug delivery paradigm in treating arthritis in transdermal delivery.

pharmacology & pharmacy
Delivery of Neutrophil Membrane Encapsulated Non-Steroidal Anti-Inflammatory Drugs by Degradable Biopolymer Microneedle Patch for Rheumatoid Arthritis Therapy

Yixuan Lin,Yang Chen,Ronghui Deng,Hao Qin,Nan Li,Yuting Qin,Hanqing Chen,Yaohua Wei,Zeming Wang,Qing Sun,Wenyi Qiu,Jian Shi,Long Chen,Yuguang Wang,Guangjun Nie,Ruifang Zhao

DOI: https://doi.org/10.1016/j.nantod.2023.101791

IF: 17.4

2023-01-01

Nano Today

Abstract:Rheumatoid arthritis (RA) is a common chronic autoimmune disease and eventually ends in severe disability and death. RA has no cure, but there are some treatments for decreasing the severity of various symptoms. For example, pain management of RA by non-steroidal anti-inflammatory drugs (NSAIDs), neutralization of the inflammatory cytokines (or block their functions) of RA by specific biologics. However, the clinical benefit is limited due to their low permeability and poor bioavailability. Meanwhile, the system toxicity for long-term use of NSAIDs is another focal issue. Herein, degradable biopolymer microneedle patch was designed and synthesized. In this dual drug delivery patch, NSAIDs were encapsulated by polymeric nanoparticles, which were coated by the neutrophil membrane, followed by loaded into the microneedle patch for local transdermal delivery. When applied to the murine models, the microneedle patch gradually dissolves and releases the contained nanoparticles. Coating of neutrophil membrane provides the nanosized NSAIDs with the capability of cytokine binding and inflammatory joint tropism. Based on inflammatory microenvironment regulation by cytokine absorption and cyclooxygenase-2 inhibition, the microneedle shows a significant local anti-inflammatory therapeutic effect on mouse model of collagen-induced arthritis and rat model of adjuvant-induced arthritis. Further development based on this advanced strategy may provide additional therapeutic options for RA treatment.
Fabrication and mechanical modelling of dissolvable PVA/PVP composite microneedles with biocompatibility for efficient transdermal delivery of ibuprofen

Min Xiao,Zifeng Wang,Yanru An,Yingqi Dai,Xinghao Wang,Zhigang Zhu

DOI: https://doi.org/10.1080/09205063.2024.2333627

2024-04-10

Journal of Biomaterials Science Polymer Edition

Abstract:Microneedles offer minimally invasive, user-friendly, and subcutaneously accessible transdermal drug delivery and have been widely investigated as an effective transdermal delivery system. Ibuprofen is a common anti-inflammatory drug to treat chronic inflammation. It is crucial to develop microneedle patches capable of efficiently delivering ibuprofen through the skin for the effective treatment of arthritis patients requiring repeated medication. In this study, the mechanical properties of a new type of polymer microneedle were studied by finite element analysis, and the experimental results showed that the microneedle could effectively deliver drugs through the skin. In addition, a high ibuprofen-loaded microneedle patch was successfully prepared by micromolding and subjected to evaluation of its infrared spectrum morphology and dissolve degree. The morphology of microneedles was characterized by scanning electron microscopy, and the mechanical properties were assessed using a built linear stretching system. In the in-vitro diffusion cell drug release test, the microneedle released 85.2 ± 1.52% (210 ± 3.7 μg) ibuprofen in the modified Franz diffusion within 4 h, exhibiting a higher drug release compared to other drug delivery methods. This study provides a portable, safe and efficient treatment approach for arthritis patients requiring daily repeated medication.

engineering, biomedical,materials science, biomaterials,polymer science
A Luteolin-Loaded Electrospun Fibrous Implantable Device for Potential Therapy of Gout Attacks.

Yi Wang,Chao Luo,Guang Yang,Xiao Wei,Dian Liu,Shaobing Zhou

DOI: https://doi.org/10.1002/mabi.201600123

2016-01-01

Macromolecular Bioscience

Abstract:The recurrence of acute gout attacks remains an unsolved problem in clinical therapy. In order to tackle this problem, poly(ε-caprolactone) (PCL)/gelatin composite fibrous devices loaded with luteolin are presented via electrospinning for the therapy of gout and its recurrence. The luteolin-loaded fibrous device has the capability of inhibiting metabolic activities and reducing inflammation-associated cytokine productions (TNF-a, IL-1β, IL-6) that are secreted by lipopolysaccharide stimulated RAW 264.7 macrophages. The device can also suppress the reaction activities of xanthine oxidase for 7 d in vitro. In vivo, acute gout model is established by injecting monosodium urate (MSU) crystals into New Zealand rabbits' knees, then the luteolin-loaded PCL/gelatin (5:5) nanofiber device is implanted near the gout sites. The results show that the device can alleviate the acute gouty arthritis. In the mean time, the luteolin-loaded PCL fiber device with a longer drug release profile is implanted in a recurrent gout model, which is constructed by injecting MSU crystals into rabbits' knees three times. The results on day 21 reveal that this device has the potential to overcome the recurrence of gout. Therefore, the drug-loaded polymer fiber device can be an inspiration for potential gout therapy to overcome recurrent attacks.
Dissolvable microneedles for transdermal drug delivery showing skin pentation and modified drug release

Irina Iachina,André H Eriksson,Malene Bertelsen,Karsten Petersson,Jörgen Jansson,Pernille Kemp,Karen M Engell,Jonathan R Brewer,Kim T Nielsen

DOI: https://doi.org/10.1016/j.ejps.2023.106371

2023-03-01

Abstract:Topical therapies for chronic skin diseases suffer from a low patient compliance due to the inconvenient treatment regimens of available products. Dissolvable microneedles (MN) with modified release offer an interesting possibility to increase the compliance by acting as a depot in the skin and thereby decreasing the dosing frequency. Furthermore, the bioavailability can be increased significantly by bypassing the barrier of the skin by the direct penetration of the MN into the skin. In this study the depot effect and skin penetration of an innovative dissolvable MN patch was assessed by insertion in ex vivo human skin and in vivo using minipigs. The MN patches are based on biodegradable polymers and the active pharmaceutical ingredients calcipotriol (Calci) and betamethasone-17-21-dipropionate (BDP) used to treat psoriasis. Using computed tomography (CT) and Coherent anti-Stokes Raman scattering (CARS) microscopy it was possible to visualize the skin penetration and follow the morphology of the MN as function of time in the skin. The depot effect was assessed by studying the modified in vitro release in an aqueous buffer and by comparing the drug release of a single application of a patch both ex vivo and in vivo to daily application of a marketed oleogel containing the same active pharmaceutical ingredients. The CT and CARS images showed efficient penetration of the MN patches into the upper dermis and a slow swelling process of the drug containing tip over a period of 8 days. Furthermore, CARS demonstrated that it can be used as a noninvasive technique with potential applicability in clinical settings. The in vitro release studies show a release of 54% over a time period of 30 days. The pharmacological relevance of MNs was confirmed in human skin explants and in vivo after single application and showed a similar response on calcipotriol and BDP mediated signaling events compared to daily application of the active oleogel. Altogether it was demonstrated that the MN can penetrate the skin and have the potential to provide a depot effect.
In Situ Polymeric Nanomicelle-Generating Dissolving Microneedle Patch for Enhanced Transdermal Methotrexate Delivery in Rheumatoid Arthritis Treatment

Ting Liu,Jintao Fu,Minglong Chen,Qiaoli Wu,Guilan Quan,Chuanbin Wu,Xin Pan

DOI: https://doi.org/10.1016/j.eurpolymj.2024.113008

IF: 6

2024-01-01

European Polymer Journal

Abstract:Rheumatoid arthritis (RA) presents a chronic autoimmune pathology. Methotrexate (MTX), a primary therapeutic agent for RA, often administered orally or via injection, has shown dose-dependent systemic toxicity upon prolonged use. Consequently, a pressing need exists for a secure and facile MTX delivery system in RA management. In the current study, the methoxy poly (ethylene glycol)-poly (lactide) polymer (mPEG-PLA) and hyaluronic acid (HA) were used as materials for both nanomicelles and dissolving microneedles (MNs) to facilitate the effective transdermal delivery of MTX in RA therapy. HA, a specific ligand for the CD44 receptor, could deposit on the outer surface of nanomicelles by interacting with mPEG-PLA, which serve as a targeting ligand for macrophages activated at inflamed joints. Upon MTX-loaded polymeric nanomicelles MNs (MTX@PMs MNs) application to the skin, MNs could effectively puncture the stratum corneum and in situ generate nanomicelles with the dissolution of MNs. In vivo therapeutic efficiency evaluations suggested that the MTX@PMs MNs demonstrated enhanced efficacy in mitigating the progression of RA without inducing treatment-related toxicity. Our findings suggest that the utilization of in situ polymeric nanomicelle-generating dissolving microneedle patches holds promise as a potential strategy for the clinical treatment of RA.
Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis

Weiman Zhao,Lijie Zheng,Jianhui Yang,Zihui Ma,Xinyi Tao,Qingqing Wang

DOI: https://doi.org/10.1080/10717544.2022.2157518

IF: 6.819

2022-12-21

Drug Delivery

Abstract:Methotrexate (MTX) is a first-line treatment for rheumatoid arthritis (RA), but its clinical use is greatly limited by the adverse effects and poor patient compliance caused by traditional oral administration or injection. In recent years, some transdermal drug delivery systems have received considerable attention due to overcoming these shortcomings. In this study, we developed dissolving microneedle patch (DMNP) for transdermal delivery of MTX to treat RA safely and effectively. The morphology, mechanical strength, skin insertion, drug content, in vitro transdermal delivery, and other properties of DMNP were characterized. Meanwhile, the adjuvant-induced arthritis model of rats was established to investigate the therapeutic effect of MTX-loaded DMNP in vivo. The results showed that the microneedles had excellent morphology with neat array and complete needles, good puncture performance and mechanical strength, and rapid intradermal dissolution rate. In vitro transdermal delivery results indicated that microneedles could significantly increase drug transdermal permeation compared with the cream group. The pharmacological study showed that MTX-loaded DMNP significantly alleviated paw swelling, inhibit inflammatory response via downregulating the levels of TNF-α and IL-1β, relieved synovium destruction with less cartilage erosion, and slowed the progression of RA in AIA rats. Besides, DMNP presented better therapeutic performance than cream or intragastric administration at the same dosage of MTX. In conclusion, the MTX-loaded dissolving microneedle patch has advantages of safety, convenience, and high efficacy over conventional administrations, laying a foundation for the transdermal drug delivery system treatment of rheumatoid arthritis.

pharmacology & pharmacy
Polymeric Microneedles Enhance Transdermal Delivery of Therapeutics

Hiep X. Nguyen,Thomas Kipping,Ajay K. Banga

DOI: https://doi.org/10.3390/pharmaceutics16070845

IF: 6.525

2024-06-22

Pharmaceutics

Abstract:This research presents the efficacy of polymeric microneedles in improving the transdermal permeation of methotrexate across human skin. These microneedles were fabricated from PLGA Expansorb® 50-2A and 50-8A and subjected to comprehensive characterization via scanning electron microscopy, Fourier-transform infrared spectroscopy, and mechanical analysis. We developed and assessed a methotrexate hydrogel for physicochemical and rheological properties. Dye binding, histological examinations, and assessments of skin integrity demonstrated the effective microporation of the skin by PLGA microneedles. We measured the dimensions of microchannels in the skin using scanning electron microscopy, pore uniformity analysis, and confocal microscopy. The skin permeation and disposition of methotrexate were researched in vitro. PLGA 50-8A microneedles appeared significantly longer, sharper, and more mechanically uniform than PLGA 50-2A needles. PLGA 50-8A needles generated substantially more microchannels, as well as deeper, larger, and more uniform channels in the skin than PLGA 50-2A needles. Microneedle insertion substantially reduced skin electrical resistance, accompanied by an elevation in transepidermal water loss values. PLGA 50-8A microneedle treatment provided a significantly higher cumulative delivery, flux, diffusion coefficient, permeability coefficient, and predicted steady-state plasma concentration; however, there was a shorter lag time than for PLGA 50-2A needles, base-treated, and untreated groups (p < 0.05). Conclusively, skin microporation using polymeric microneedles significantly improved the transdermal delivery of methotrexate.

pharmacology & pharmacy
Hyaluronic acid dissolving microneedle patch-assisted acupoint transdermal delivery of triptolide for effective rheumatoid arthritis treatment

Siyao Li,Quanlong Chen,Yanglin Zhang,Di Wang,Huiling Hu,Jingjing Li,Chen Zhang,Jinming Zhang

DOI: https://doi.org/10.1038/s41598-024-76341-w

IF: 4.6

2024-10-25

Scientific Reports

Abstract:Triptolide (TP), a major active component of the herb Tripterygium wilfordii Hook F, has been shown excellent pharmacological effects on rheumatoid arthritis. However, TP is prone to causing severe organ toxicity, which limits its clinical application. In recent years, microneedle technology has provided a new option for the treatment of arthritis due to its advantages of efficient local transdermal drug delivery. In this study, we constructed a microneedle platform to deliver TP locally to the joints, thereby enhancing TP penetration and reducing systemic toxicity. Additionally, we investigated whether acupoint drug delivery can produce a synergistic effect of needles and drugs. First, TP was loaded into microneedles using polyvinylpyrrolidone and hyaluronic acid as matrix materials. Next, we established a rat adjuvant-induced arthritis (AIA) model to evaluate the therapeutic effect of TP-loaded microneedles. The experiments showed that TP-loaded microneedles alleviated the AIA rats' inflammatory response, joint swelling, and bone erosion. However, there was no significant difference in the therapeutic effect observed in the acupoint and non-acupoint administration groups. In conclusion, TP-loaded microneedles have the advantages of safety, convenience, and high efficacy over conventional administration routes, laying a foundation for the transdermal drug delivery system-based treatment of rheumatoid arthritis.

multidisciplinary sciences
[Two cases of cancer of the esophagus complicated with pneumoconiosis (author's transl)].

S. Oshima,M. Sakamoto,R. Innami,H. Nakahara,E. Gu,A. Kurisu,K. Ishizuka

1981-11-01

Abstract:

Shaft orbit pattern recognition for fault diagnosis of Induction motor using Neural Network

Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model

Rapidly separating dissolving microneedles with sustained-release colchicine and stabilized uricase for simplified long-term gout management

Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects

Trial of ABO and Rh blood typing with an automated blood cell counter.

Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons

Preparation of combined colchicine with loxoprofen sodium loaded in dissolvable microneedles and its anti-gouty arthritis effect

Core–shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis

Glycyrrhizic acid modified Poria cocos polyscaccharide carbon dots dissolving microneedles for methotrexate delivery to treat rheumatoid arthritis

Multimodal smart systems reprogramme macrophages and remove urate to treat gouty arthritis

Promising Strategies for Transdermal Delivery of Arthritis Drugs: Microneedle Systems

Delivery of Neutrophil Membrane Encapsulated Non-Steroidal Anti-Inflammatory Drugs by Degradable Biopolymer Microneedle Patch for Rheumatoid Arthritis Therapy

Fabrication and mechanical modelling of dissolvable PVA/PVP composite microneedles with biocompatibility for efficient transdermal delivery of ibuprofen

A Luteolin-Loaded Electrospun Fibrous Implantable Device for Potential Therapy of Gout Attacks.

Dissolvable microneedles for transdermal drug delivery showing skin pentation and modified drug release

In Situ Polymeric Nanomicelle-Generating Dissolving Microneedle Patch for Enhanced Transdermal Methotrexate Delivery in Rheumatoid Arthritis Treatment

Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis

Polymeric Microneedles Enhance Transdermal Delivery of Therapeutics

Hyaluronic acid dissolving microneedle patch-assisted acupoint transdermal delivery of triptolide for effective rheumatoid arthritis treatment

[Two cases of cancer of the esophagus complicated with pneumoconiosis (author's transl)].